Despite aggressive clinical treatment, recurrence of glioblastoma multiforme (GBM) is unavoidable, and the clinical outcome is still poor. A convincing explanation is the phenotypic transition of GBM cells upon aggressive treatment such as radiotherapy. However, the microenvironmental factors contributing to GBM recurrence after treatment remain unexplored. Here, it is shown that radiation-treated GBM cells produce soluble intercellular adhesion molecule-1 (sICAM-1) which stimulates the infiltration of macrophages, consequently enriching the tumor microenvironment with inflammatory macrophages. Acting as a paracrine factor, tumor-derived sICAM-1 induces macrophages to secrete wingless-type MMTV integration site family, member 3A (WNT3A), wh...
Glioblastoma multiforme (GBM) is the most lethal primary central nervous system tumor, with median s...
The tumor microenvironment plays an essential role in supporting glioma stemness and radioresistance...
Radiation therapy (RT) remains the front-line treatment for high-grade gliomas; however, tumor recur...
Glioblastoma, is the most frequent and malignant primary brain tumor. Despite modern surgical and me...
Glioblastoma multiforme (GBM) is a lethal brain tumor with a mean survival time of 1 year. One major...
High grade gliomas (HGG) are classified into four subgroups based on transcriptional signatures and ...
Tumor-associated macrophages (TAMs) and microglia (MG) are potent regulators of glioma development a...
Evidence is accumulating that the tumour microenvironment (TME) has a key role in the progression of...
Glioma-associated microglia and macrophages (GAMs) and myeloid-derived suppressor cells (MDSCs) cond...
Glioblastoma multiforme (GBM) is the most lethal primary central nervous system tumor, with median s...
Background: Glioblastoma (GBM) is a complex disease with extensive molecular and transcriptional het...
Glioblastoma multiforme (GBM) is the most lethal and aggressive type of primary brain malignancy. Fa...
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence i...
Glioblastomas (GBM) are the most malignant brain tumors, which are thought to originate from neoplas...
Gliomas are the most common, highly malignant, and deadliest forms of brain tumors. These intra-cran...
Glioblastoma multiforme (GBM) is the most lethal primary central nervous system tumor, with median s...
The tumor microenvironment plays an essential role in supporting glioma stemness and radioresistance...
Radiation therapy (RT) remains the front-line treatment for high-grade gliomas; however, tumor recur...
Glioblastoma, is the most frequent and malignant primary brain tumor. Despite modern surgical and me...
Glioblastoma multiforme (GBM) is a lethal brain tumor with a mean survival time of 1 year. One major...
High grade gliomas (HGG) are classified into four subgroups based on transcriptional signatures and ...
Tumor-associated macrophages (TAMs) and microglia (MG) are potent regulators of glioma development a...
Evidence is accumulating that the tumour microenvironment (TME) has a key role in the progression of...
Glioma-associated microglia and macrophages (GAMs) and myeloid-derived suppressor cells (MDSCs) cond...
Glioblastoma multiforme (GBM) is the most lethal primary central nervous system tumor, with median s...
Background: Glioblastoma (GBM) is a complex disease with extensive molecular and transcriptional het...
Glioblastoma multiforme (GBM) is the most lethal and aggressive type of primary brain malignancy. Fa...
Glioblastoma multiforme (GBM) is the most aggressive, infiltrative brain cancer. Tumour recurrence i...
Glioblastomas (GBM) are the most malignant brain tumors, which are thought to originate from neoplas...
Gliomas are the most common, highly malignant, and deadliest forms of brain tumors. These intra-cran...
Glioblastoma multiforme (GBM) is the most lethal primary central nervous system tumor, with median s...
The tumor microenvironment plays an essential role in supporting glioma stemness and radioresistance...
Radiation therapy (RT) remains the front-line treatment for high-grade gliomas; however, tumor recur...